Hypertension Journal

Register      Login

VOLUME 3 , ISSUE 3 ( July-September, 2017 ) > List of Articles


Renal Effects of Sodium-glucose-linked Transporter 2 Inhibitors

M Rajasekara Chakravarthi, Hari K Marri

Citation Information : Chakravarthi MR, Marri HK. Renal Effects of Sodium-glucose-linked Transporter 2 Inhibitors. Hypertens J 2017; 3 (3):154-160.

DOI: 10.5005/jp-journals-10043-0087

License: CC BY 3.0

Published Online: 01-12-2017

Copyright Statement:  Copyright © 2017; The Author(s).


How to cite this article

Chakravarthi MR, Marri HK. Renal Effects of Sodium-glucose-linked Transporter 2 Inhibitors. Hypertens J 2017;3(3):154-160.

  1. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011 Dec;94(3):311-321.
  2. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007 Oct;18(10):2644-2648.
  3. Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area. BMC Nephrol 2012 Aug;13(1):87.
  4. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009 Nov;31(11):2608-2617.
  5. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010 Feb;27(2):136-142.
  6. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012 Jan;14(1):5-14.
  7. The relationship of kidney function to the glucose utilization of the extra abdominal tissues. Am J Physiol 1938 Nov;124(2):279-284.
  8. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001 Feb;24(2):382-391.
  9. Glucose handling by the kidney. Kidney Int (Suppl) 2011 Mar;120:S1-S6.
  10. Biology of human sodium glucose transporters. Physiol Rev 2011 Apr;91(2):733-794.
  11. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982 Mar;72(3):375-380.
  12. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981 Mar;19(3):410-415.
  13. The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy. Acta Endocrinol Suppl (Copenh) 1981;97(242):7-10.
  14. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009 Apr;52(4):691-697.
  15. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012 Oct;35(10):2061-2068.
  16. The clinical significance of hyperfiltration in diabetes. Diabetologia 2010 Oct;53(10):2093-2104.
  17. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008 Jul;2008:305403.
  18. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011 Aug;32(4):515-531.
  19. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012 Jan;302(1):R75-R83.
  20. The renal effects of SGLT2 inhibitors and a mini-review of the literature. Ther Adv Endocrinol Metab 2016 Dec;7(5-6):212-228.
  21. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double- blind, placebo-controlled, phase III trial. Diabetes Care 2010 Oct;33(10): 2217-2224.
  22. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014 Mar;13:65.
  23. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012 Jun;14(6):539-545.
  24. SGLT2 inhibitors and the diabetic kidney. Diabetes Care 2016 Aug;39(Suppl 2):S165-S171.
  25. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014 Apr;85(4):962-971.
  26. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014 Oct;16(10):1016-1027.
  27. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014 May;2(5):369-384.
  28. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017 Aug;377:644-657.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.